National Comprehensive Cancer Network (NCCN) Guidelines
The NCCN recommends the following screening for people at increased risk for pancreatic cancer:
The NCCN recommends that people with inherited mutations in the following genes (with or without a family history of cancer) "consider pancreatic cancer screening" with MRCP or EUS:
NCCN guidelines recommend that people with an inherited mutation in one of the following genes and a family history of cancer "consider pancreatic cancer screening" with MRCP or EUS, beginning at age 50 or 10 years earlier than the earliest pancreatic cancer diagnosis in the family: ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, EPCAM, PALB2, TP53.
The NCCN does not currently recommend pancreatic cancer screening for people with the above mutations who do not have a family history of cancer.
American Society for Gastrointestinal Endoscopy (ASGE) Guidelines
In February 2022, the ASGE released updated guidelines on pancreatic cancer screening for people with a BRCA1 or BRCA2 mutation. These guidelines recommended:
The following studies are looking at risk management for pancreatic cancer:
A number of other clinical trials for pancreatic cancer screening and prevention may be found here.
The organization, Collaborative Group of the Americas- Inherited Gastrointestinal Cancer (CGA-IGC) curates an updated list of hospitals and programs with expertise in pancreatic cancer screening for high-risk people.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.